Câncer de mama invasivo primário

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis [internet publication].Texto completo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].Texto completo

Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb;35(2):159-82.Texto completo  Resumo

Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2016 Jul 10;34(20):2416-27.Texto completo  Resumo

Park KU, Somerfield MR, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025 May 10;43(14):1720-41.Texto completo  Resumo

1. Amin MB, Edge S, Greene, F, et al, eds. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

2. WHO Classification of Tumours Editorial Board. WHO classification of breast tumours. 5th ed. Lyon: IARC Press; 2019.

3. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. Resumo

4. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23.Texto completo  Resumo

5. Mamouch F, Berrada N, Aoullay Z, et al. Inflammatory breast cancer: a literature review. World J Oncol. 2018 Nov;9(5-6):129-35.Texto completo  Resumo

6. Cserni G, Charafe-Jauffret E, van Diest PJ. Inflammatory breast cancer: the pathologists' perspective. Eur J Surg Oncol. 2018 Aug;44(8):1128-34. Resumo

7. Sandoval-Leon AC, Drews-Elger K, Gomez-Fernandez CR, et al. Paget's disease of the nipple. Breast Cancer Res Treat. 2013 Aug;141(1):1-12. Resumo

8. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-63.Texto completo  Resumo

9. National Cancer Institute. Cancer stat facts: female breast cancer. 2025 [internet publication].Texto completo

10. Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45.Texto completo  Resumo

11. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19;356(16):1670-4.Texto completo  Resumo

12. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229-39.Texto completo  Resumo

13. Pfeiffer RM, Webb-Vargas Y, Wheeler W, et al. Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1214-22.Texto completo  Resumo

14. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001 Oct 27;358(9291):1389-99. Resumo

15. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996 Jun 1;77(11):2318-24. Resumo

16. Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005 Oct;18(10):1305-20.Texto completo  Resumo

17. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010 May;12(5):245-59. Resumo

18. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017 Jun 20;317(23):2402-16.Texto completo  Resumo

19. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000 Nov;83(10):1301-8. Resumo

20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, pancreatic, and prostate [internet publication].Texto completo

21. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002 Apr 17;94(8):606-16.Texto completo  Resumo

22. Endogenous Hormones and Breast Cancer Collaborative Group; Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011 Aug 23;105(5):709-22.Texto completo  Resumo

23. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33.Texto completo  Resumo

24. Mørch LS, Hannaford PC, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2018 Mar 29;378(13):1265-6. Resumo

25. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019 Sep 28;394(10204):1159-68.Texto completo  Resumo

26. Jaiyesimi IA, Buzdar AU, Hortobagyi GN. Inflammatory breast cancer: a review. J Clin Oncol. 1992 Jun;10(6):1014-24. Resumo

27. Lynch HT, Lynch JF. Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet. 1986 Aug;22(4):369-71. Resumo

28. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998 May;16(5):1969-77. Resumo

29. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Nov 2023 [internet publication].Texto completo

30. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015 Jul 20;33(21):2345-52.Texto completo  Resumo

31. American College of Radiology. ACR appropriateness criteria: transgender breast cancer screening. 2021 [internet publication].Texto completo

32. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005 Mar 16;97(6):439-48.Texto completo  Resumo

33. Bhargava S, Moen K, Qureshi SA, et al. Mammographic screening attendance among immigrant and minority women: a systematic review and meta-analysis. Acta Radiol. 2018 Nov;59(11):1285-91.Texto completo  Resumo

34. Sung H, DeSantis CE, Fedewa SA, et al. Breast cancer subtypes among Eastern-African-born black women and other black women in the United States. Cancer. 2019 Oct 1;125(19):3401-11.Texto completo  Resumo

35. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401-8.Texto completo  Resumo

36. Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist. 2003;8(5):466-73.Texto completo  Resumo

37. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA. 1993 Oct 6;270(13):1563-8. Resumo

38. Stratton MR. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997 May 24;349(9064):1505-10. Resumo

39. Anderson DE, Badzioch MD. Familial breast cancer risks. Effects of prostate and other cancers. Cancer. 1993 Jul 1;72(1):114-9. Resumo

40. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45.Texto completo  Resumo

41. Breast Cancer Association Consortium, Mavaddat N, Dorling L, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 2022 Mar 1;8(3):e216744.Texto completo  Resumo

42. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996 May;13(1):123-5. Resumo

43. Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med. 2021 Feb 4;384(5):428-39.Texto completo  Resumo

44. Kvale G, Heuch I. Menstrual factors and breast cancer risk. Cancer. 1988 Oct 15;62(8):1625-31. Resumo

45. Chen WY, Colditz GA. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol. 2007 Jul;4(7):415-23. Resumo

46. Sangaramoorthy M, Hines LM, Torres-Mejía G, et al. A pooled analysis of breastfeeding and breast cancer risk by hormone receptor status in parous Hispanic women. Epidemiology. 2019 May;30(3):449-57.Texto completo  Resumo

47. Jeong SH, An YS, Choi JY, et al. Risk reduction of breast cancer by childbirth, breastfeeding, and their interaction in Korean women: heterogeneous effects across menopausal status, hormone receptor status, and pathological subtypes. J Prev Med Public Health. 2017 Nov;50(6):401-10.Texto completo  Resumo

48. Nichols HB, Schoemaker MJ, Cai J, et al. Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies. Ann Intern Med. 2019 Jan 1;170(1):22-30.Texto completo  Resumo

49. Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women's Health Initiative randomized clinical trials. JAMA Oncol. 2015 Jun;1(3):296-305.Texto completo  Resumo

50. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020 Jul 28;324(4):369-80.Texto completo  Resumo

51. Gartlehner G, Patel SV, Reddy S, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 Nov 1;328(17):1747-65.Texto completo  Resumo

52. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US Preventive Services Task Force recommendation statement. JAMA. 2022 Nov 1;328(17):1740-46.Texto completo  Resumo

53. Schatzkin A, Jones DY, Hoover RN, et al. Alcohol consumption and breast cancer in the epidemiologic follow-up study of the first National Health and Nutrition Examination Survey. N Engl J Med. 1987 May 7;316(19):1169-73. Resumo

54. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998 Feb 18;279(7):535-40. Resumo

55. Zhang SM, Lee IM, Manson JE, et al. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol. 2007 Mar 15;165(6):667-76.Texto completo  Resumo

56. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction [internet publication].Texto completo

57. Suzuki R, Ye W, Rylander-Rudqvist T, et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. Natl Cancer Inst. 2005 Nov 2;97(21):1601-8.Texto completo  Resumo

58. Zhang SM, Hankinson SE, Hunter DJ, et al. Folate intake and risk of breast cancer characterized by hormone receptor status. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2004-8.Texto completo  Resumo

59. Roychoudhuri R, Evans H, Robinson D, et al. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer. 2004 Aug 31;91(5):868-72. Resumo

60. van Barele M, Akdeniz D, Heemskerk-Gerritsen BAM, et al. Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation. J Natl Cancer Inst. 2023 Nov 8;115(11):1318-28.Texto completo  Resumo

61. Kenney LB, Yasui Y, Inskip PD, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med. 2004 Oct 19;141(8):590-7. Resumo

62. Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol. 2005 Jan 1;23(1):197-204.Texto completo  Resumo

63. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010 Apr 6;152(7):444-55; W144-54.Texto completo  Resumo

64. John EM, Kelsey JL. Radiation and other environmental exposures and breast cancer. Epidemiol Rev. 1993;15(1):157-62. Resumo

65. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003 Jul 23;290(4):465-75.Texto completo  Resumo

66. De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009 Sep 10;27(26):4239-46.Texto completo  Resumo

67. Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res. 2005;7(1):21-32.Texto completo  Resumo

68. Brenner AV, Preston DL, Sakata R, et al. Incidence of breast cancer in the life span study of atomic bomb survivors: 1958-2009. Radiat Res. 2018 Oct;190(4):433-44.Texto completo  Resumo

69. Yeh JM, Lowry KP, Schechter CB, et al. Clinical benefits, harms, and cost-effectiveness of breast cancer screening for survivors of childhood cancer treated with chest radiation: a comparative modeling study. Ann Intern Med. 2020 Sep 1;173(5):331-41.Texto completo  Resumo

70. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993 Feb 15;71(4):1258-65. Resumo

71. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985 Jan 17;312(3):146-51. Resumo

72. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005 Jul 21;353(3):229-37.Texto completo  Resumo

73. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007 Jan 18;356(3):227-36.Texto completo  Resumo

74. Bodewes FTH, van Asselt AA, Dorrius MD, et al. Mammographic breast density and the risk of breast cancer: a systematic review and meta-analysis. Breast. 2022 Dec;66:62-8.Texto completo  Resumo

75. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69.Texto completo  Resumo

76. Kerlikowske K, Ichikawa L, Miglioretti DL, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst. 2007 Mar 7;99(5):386-95.Texto completo  Resumo

77. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis [internet publication].Texto completo

78. Monticciolo DL, Malak SF, Friedewald SM, et al. Breast cancer screening recommendations inclusive of all women at average risk: update from the ACR and society of breast imaging. J Am Coll Radiol. 2021 Sep;18(9):1280-8.Texto completo  Resumo

79. ​American College of Radiology. ACR appropriateness criteria: supplemental breast cancer screening based on breast density. 2024 [internet publication].Texto completo

80. Arasu VA, Miglioretti DL, Sprague BL, et al. Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk. J Clin Oncol. 2019 Apr 20;37(12):954-63.Texto completo  Resumo

81. Thompson CM, Mallawaarachchi I, Dwivedi DK, et al. The association of background parenchymal enhancement at breast MRI with breast cancer: a systematic review and meta-analysis. Radiology. 2019 Sep;292(3):552-61.Texto completo  Resumo

82. Hermelink R, Leitzmann MF, Markozannes G, et al. Sedentary behavior and cancer: an umbrella review and meta-analysis. Eur J Epidemiol. 2022 May;37(5):447-60.Texto completo  Resumo

83. Chan DSM, Abar L, Cariolou M, et al. World Cancer Research Fund International: continuous update project - systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes Control. 2019 Nov;30(11):1183-200.Texto completo  Resumo

84. Wang YC, Lin CH, Huang SP, et al. Risk factors for female breast cancer: a population cohort study. Cancers (Basel). 2022 Feb 3;14(3):788.Texto completo  Resumo

85. Lee J, Lee J, Lee DW, et al. Sedentary work and breast cancer risk: a systematic review and meta-analysis. J Occup Health. 2021 Jan;63(1):e12239.Texto completo  Resumo

86. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA. 2003 Sep 10;290(10):1331-6.Texto completo  Resumo

87. Teras LR, Patel AV, Wang M, et al. Sustained weight loss and risk of breast cancer in women ≥50 years: a pooled analysis of prospective data. J Natl Cancer Inst. 2020 Sep 1;112(9):929-37.Texto completo  Resumo

88. Bernstein L, Henderson BE, Hanisch R, et al. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst. 1994 Sep 21;86(18):1403-8. Resumo

89. Enger SM, Bernstein L. Exercise activity, body size and premenopausal breast cancer survival. Br J Cancer. 2004 Jun 1;90(11):2138-41.Texto completo  Resumo

90. Margolis KL, Mucci L, Braaten T, et al. Physical activity in different periods of life and the risk of breast cancer: the Norwegian-Swedish Women's Lifestyle and Health cohort study. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):27-32.Texto completo  Resumo

91. Dixon-Suen SC, Lewis SJ, Martin RM, et al. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. Br J Sports Med. 2022 Oct;56(20):1157-70.Texto completo  Resumo

92. Key TJ, Bradbury KE, Perez-Cornago A, et al. Diet, nutrition, and cancer risk: what do we know and what is the way forward? BMJ. 2020 Mar 5;368:m511.Texto completo  Resumo

93. Thiebaut AC, Kipnis V, Chang SC, et al. Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst. 2007 Mar 21;99(6):451-62. Resumo

94. Boyd NF, Stone J, Vogt KN, et al. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. Br J Cancer. 2003 Nov 3;89(9):1672-85. Resumo

95. Ubago-Guisado E, Rodríguez-Barranco M, Ching-López A, et al. Evidence update on the relationship between diet and the most common cancers from the European prospective investigation into cancer and nutrition (EPIC) study: a systematic review. Nutrients. 2021 Oct 13;13(10):3582.Texto completo  Resumo

96. Farvid MS, Barnett JB, Spence ND. Fruit and vegetable consumption and incident breast cancer: a systematic review and meta-analysis of prospective studies. Br J Cancer. 2021 Jul;125(2):284-98.Texto completo  Resumo

97. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 8;295(6):629-42.Texto completo  Resumo

98. Martin LJ, Li Q, Melnichouk O, et al. A randomized trial of dietary intervention for breast cancer prevention. Cancer Res. 2011 Jan 1;71(1):123-33.Texto completo  Resumo

99. Yu M, Tatalovich Z, Gibson JT, et al. Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control. 2014 Jan;25(1):81-92. Resumo

100. Coughlin SS. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res Treat. 2019 Oct;177(3):537-48. Resumo

101. Bjerkaas E, Parajuli R, Weiderpass E, et al. Smoking duration before first childbirth: an emerging risk factor for breast cancer? Results from 302,865 Norwegian women. Cancer Causes Control. 2013 Jul;24(7):1347-56.Texto completo  Resumo

102. Catsburg C, Miller AB, Rohan TE. Active cigarette smoking and risk of breast cancer. Int J Cancer. 2015 May 1;136(9):2204-9.Texto completo  Resumo

103. Macacu A, Autier P, Boniol M, et al. Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2015 Nov;154(2):213-24. Resumo

104. He Y, Si Y, Li X, et al. The relationship between tobacco and breast cancer incidence: a systematic review and meta-analysis of observational studies. Front Oncol. 2022 Sep 15;12:961970.Texto completo  Resumo

105. Benn M, Tybjærg-Hansen A, Smith GD, et al. High body mass index and cancer risk - a Mendelian randomisation study. Eur J Epidemiol. 2016 Sep;31(9):879-92. Resumo

106. Schoemaker MJ, Nichols HB, Wright LB, et al; Premenopausal Breast Cancer Collaborative Group. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 2018 Nov 1;4(11):e181771.Texto completo  Resumo

107. Wang J, Yang DL, Chen ZZ, et al. Associations of body mass index with cancer incidence among populations, genders, and menopausal status: a systematic review and meta-analysis. Cancer Epidemiol. 2016 Jun;42:1-8. Resumo

108. Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017 Feb 28;356:j477.Texto completo  Resumo

109. Feigelson HS, Caan B, Weinmann S, et al. Bariatric surgery is associated with reduced risk of breast cancer in both premenopausal and postmenopausal women. Ann Surg. 2020 Dec;272(6):1053-9. Resumo

110. Mukherjee Das A, Gogia A, Garg M, et al. Urinary concentration of endocrine-disrupting phthalates and breast cancer risk in Indian women: a case-control study with a focus on mutations in phthalate-responsive genes. Cancer Epidemiol. 2022 Aug;79:102188. Resumo

111. Ahern TP, Broe A, Lash TL, et al. Phthalate exposure and breast cancer incidence: a Danish nationwide cohort study. J Clin Oncol. 2019 Jul 20;37(21):1800-9.Texto completo  Resumo

112. Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR. J Am Coll Radiol. 2023 Sep;20(9):902-14. Resumo

113. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins - Gynecology. ACOG Practice Bulletin No.179: breast cancer risk assessment and screening in average-risk women. Obstet Gynecol. 2017 Jul;130(1):e1-16. Resumo

114. Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019 Nov 20;37(33):3152-65.Texto completo  Resumo

115. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Sep 3;322(9):857-67.Texto completo  Resumo

116. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. Resumo

117. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.Texto completo  Resumo

118. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015 Jan;16(1):67-75.Texto completo  Resumo

119. Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019 Apr 29;(4):CD012191.Texto completo  Resumo

120. Nelson HD, Fu R, Zakher B, Pappas M, et al. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019 Sep 3;322(9):868-86.Texto completo  Resumo

121. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21;295(23):2727-41.Texto completo  Resumo

122. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010 Jun;3(6):696-706.Texto completo  Resumo

123. Sessa C, Balmaña J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023 Jan;34(1):33-47.Texto completo

124. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Aug 20;322(7):652-65.Texto completo  Resumo

125. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].Texto completo

126. Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg. 2014 Dec;260(6):1000-10. Resumo

127. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15;22(6):1055-62.Texto completo  Resumo

128. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999 Jan 14;340(2):77-84.Texto completo  Resumo

129. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001 Jul 19;345(3):159-64.Texto completo  Resumo

130. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008 Mar 10;26(8):1331-7.Texto completo  Resumo

131. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967-75.Texto completo  Resumo

132. Eleje GU, Eke AC, Ezebialu IU, et al. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018 Aug 24;(8):CD012464.Texto completo  Resumo

133. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015 Mar 18;107(5):djv033. Resumo

134. Terry MB, Daly MB, Phillips KA, et al. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. J Natl Cancer Inst. 2019 Mar 1;111(3):331-4.Texto completo  Resumo

135. Choi YH, Terry MB, Daly MB, et al. Association of risk-reducing salpingo-oophorectomy with breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2021 Apr 1;7(4):585-92.Texto completo  Resumo

136. Ho CM, Mak CK, Lau Y, et al. Skin involvement in invasive breast carcinoma: safety of skin-sparing mastectomy. Ann Surg Oncol. 2003 Mar;10(2):102-7. Resumo

137. Gajdos C, Tartter PI, Bleiweiss IJ, et al. Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann Surg. 2002 Feb;235(2):246-51.Texto completo  Resumo

138. American College of Radiology​. BI-RADS®: ACR breast imaging reporting and data system. [internet publication].Texto completo

139. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):143-7. Resumo

140. Fisher ER, Gregorio RM, Fisher B, et al. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975 Jul;36(1):1-85.Texto completo  Resumo

141. American College of Radiology. ACR practice parameter for the performance of screening and diagnostic mammography. 2023 [internet publication].Texto completo

142. American College of Radiology. ACR appropriateness criteria: palpable breast masses. 2022 [internet publication].Texto completo

143. Moss HA, Britton PD, Flower CD, et al. How reliable is modern breast imaging in differentiating benign from malignant breast lesions in the symptomatic population? Clin Radiol. 1999 Oct;54(10):676-82. Resumo

144. Kim WH, Chang JM, Moon HG, et al. Comparison of the diagnostic performance of digital breast tomosynthesis and magnetic resonance imaging added to digital mammography in women with known breast cancers. Eur Radiol. 2016 Jun;26(6):1556-64. Resumo

145. Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb;35(2):159-82.Texto completo  Resumo

146. Expert Panel on Breast Imaging, McDonald ES, Scheel JR, et al. ACR appropriateness criteria: imaging of invasive breast cancer. J Am Coll Radiol. 2024 Jun;21(6s):S168-202.Texto completo  Resumo

147. American College of Radiology. ACR appropriateness criteria: imaging of the axilla. 2021 [internet publication].Texto completo

148. American College of Radiology. ACR practice parameter for the performance of a breast ultrasound examination. 2021 [internet publication].Texto completo

149. Flobbe K, Bosch AM, Kessels AG, et al. The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. Arch Intern Med. 2003 May 26;163(10):1194-9.Texto completo  Resumo

150. Expert Panel on Breast Imaging, Hayward JH, Linden OE, et al. ACR Appropriateness Criteria® monitoring response to neoadjuvant systemic therapy for breast cancer: 2022 Update. J Am Coll Radiol. 2023 May;20(5s):S125-45.Texto completo  Resumo

151. Bin L, Huihui Y, Weiping Y, et al. Value of three-dimensional ultrasound in differentiating malignant from benign breast tumors: a systematic review and meta-analysis. Ultrasound Q. 2019 Mar;35(1):68-73.Texto completo  Resumo

152. D’Orsi CJ, Sickles EA, Mendelson EB, et al. ACR BI-RADS Atlas, breast imaging reporting and data system. 5th ed. Reston,VA: American College of Radiology; 2013​.

153. Maxwell AJ, Ridley NT, Rubin G, et al. The Royal College of Radiologists Breast Group breast imaging classification. Clin Radiol. 2009 Jun;64(6):624-7.Texto completo  Resumo

154. Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004 Dec 8;292(22):2735-42.Texto completo  Resumo

155. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010 Feb 13;375(9714):563-71. Resumo

156. American College of Radiology.​ ACR practice parameter for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast. 2023 [internet publication].Texto completo

157. American College of Radiology. ACR appropriateness criteria: breast imaging during pregnancy. 2025 [internet publication].Texto completo

158. Loibl S, Azim HA Jr, Bachelot T, et al. ESMO expert consensus statements on the management of breast cancer during pregnancy (PrBC). Ann Oncol. 2023 Oct;34(10):849-66.Texto completo  Resumo

159. Ljung BM, Drejet A, Chiampi N, et al. Diagnostic accuracy of fine-needle aspiration biopsy is determined by physician training in sampling technique. Cancer. 2001 Aug 25;93(4):263-8.Texto completo  Resumo

160. Allison KH, Hammond ME, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020 Apr 20;38(12):1346-66.Texto completo  Resumo

161. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023 Aug 1;41(22):3867-72.Texto completo  Resumo

162. Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019 May 20;37(15):1305-15.Texto completo  Resumo

163. Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. J Clin Oncol. 2024 Feb 10;42(5):584-604.Texto completo  Resumo

164. Tung N, Ricker C, Messersmith H, et al. Selection of germline genetic testing panels in patients with cancer: ASCO guideline. J Clin Oncol. 2024 Jul 20;42(21):2599-615.Texto completo  Resumo

165. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015 Nov 19;373(21):2005-14.Texto completo  Resumo

166. Goncalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw. 2013 Feb 1;11(2):174-82.Texto completo  Resumo

167. Harbeck N, Sotlar K, Wuerstlein R, et al. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat Rev. 2014 Apr;40(3):434-44. Resumo

168. Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019 Jun 20;380(25):2395-405.Texto completo  Resumo

169. Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022 Jun 1;40(16):1816-37.Texto completo  Resumo

170. National Institute for Health and Care Excellence. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Dec 2018 [internet publication]Texto completo

171. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30;351(27):2817-26.Texto completo  Resumo

172. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018 Jul 12;379(2):111-21.Texto completo  Resumo

173. Sparano JA, Gray RJ, Makower DF, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol. 2019 Sep 30;6(3):367-74.Texto completo  Resumo

174. Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021 Dec 16;385(25):2336-47.Texto completo  Resumo

175. Seltzer MH, Perloff LJ, Kelley RI, et al. The significance of age in patients with nipple discharge. Surg Gynecol Obstet. 1970 Sep;131(3):519-22. Resumo

176. Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980 Jun 15;45(12):2917-24. Resumo

177. Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018 Aug;170(3):647-56.Texto completo  Resumo

178. Fiorca JV. Fibrocystic changes. Obstet Gynecol Clin North Am. 11994 Sep;21(3):445-52. Resumo

179. Courtillot C, Plu-Bureau G, Binart N, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35. Resumo

180. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4;(6):CD001877.Texto completo  Resumo

181. Richman IB, Long JB, Soulos PR, et al. Estimating breast cancer overdiagnosis after screening mammography among older women in the United States. Ann Intern Med. 2023 Sep;176(9):1172-80.Texto completo  Resumo

182. American College of Radiology. ACR appropriateness criteria: male breast cancer screening. 2025 [internet publication]​.Texto completo

183. Bobo JK, Lee NC, Thames SF, et al. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst. 2000 Jun 21;92(12):971-6.Texto completo  Resumo

184. UK National Screening Committee. Adult screening programme:​ breast cancer. Dec 2019 [internet publication].Texto completo

185. European Commission. European guidelines on breast cancer screening and diagnosis. Nov 2017 [internet publication].Texto completo

186. US Preventive Services Task Force, Nicholson WK, Silverstein M, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024 Jun 11;331(22):1918-30.Texto completo  Resumo

187. Oeffinger KC, Fontham ET, Etzioni R, et al; American Cancer Society. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614.Texto completo  Resumo

188. Age to initiate routine breast cancer screening: ACOG clinical practice update. Obstet Gynecol. 2025 Jan 1;145(1):e40-4. Resumo

189. Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024 Jun 11;331(22):1947-60.Texto completo  Resumo

190. American College of Radiology. ACR Appropriateness Criteria: female breast cancer screening​. 2025 [internet publication].Texto completo

191. Phi XA, Tagliafico A, Houssami N, et al. Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis. BMC Cancer. 2018 Apr 3;18(1):380.Texto completo  Resumo

192. Houssami N, Zackrisson S, Blazek K, et al. Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening. Eur J Cancer. 2021 May;148:14-23. Resumo

193. Marinovich ML, Hunter KE, Macaskill P, et al. Breast cancer screening using tomosynthesis or mammography: a meta-analysis of cancer detection and recall. J Natl Cancer Inst. 2018 Sep 1;110(9):942-9.Texto completo  Resumo

194. Yun SJ, Ryu CW, Rhee SJ, et al. Benefit of adding digital breast tomosynthesis to digital mammography for breast cancer screening focused on cancer characteristics: a meta-analysis. Breast Cancer Res Treat. 2017 Aug;164(3):557-69. Resumo

195. Chen HL, Zhou JQ, Chen Q, et al. Comparison of the sensitivity of mammography, ultrasound, magnetic resonance imaging and combinations of these imaging modalities for the detection of small (≤2 cm) breast cancer. Medicine (Baltimore). 2021 Jul 2;100(26):e26531.Texto completo  Resumo

196. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012 Apr 4;307(13):1394-404.Texto completo  Resumo

197. Harada-Shoji N, Suzuki A, Ishida T, et al. Evaluation of adjunctive ultrasonography for breast cancer detection among women aged 40-49 years with varying breast density undergoing screening mammography: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2021 Aug 2;4(8):e2121505.Texto completo  Resumo

198. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89. Resumo

199. American College of Obstetrics and Gynecology. Committee opinion no. 625: management of women with dense breasts diagnosed by mammography. Obstet Gynecol. 2015 Mar;125(3):750-1.Texto completo  Resumo

200. US Food and Drug Administration. ​Important information: final rule to amend the Mammography Quality Standards Act (MQSA). Sep 2024 [internet publication].Texto completo

201. American College of Obstetricians and Gynecologists. Practice advisory to committee opinion no. 625: management of women with dense breasts diagnosed by mammography. Apr 2023 [internet publication]Texto completo

202. NHS England. Breast screening: very high risk women surveillance protocols. Sep 2024 [internet publication].Texto completo

203. NHS England. ​Tests and frequency of testing for women at very high risk. Sep 2024 [internet publication].Texto completo

204. Expert Panel on Breast Imaging, Niell BL, Jochelson MS, et al. ACR appropriateness criteria® female breast cancer screening: 2023 update. J Am Coll Radiol. 2024 Jun;21(6s):S126-43.Texto completo  Resumo

205. American College of Radiology. ACR appropriateness criteria: breast imaging lactating women. 2025 [internet publication].Texto completo

206. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019 Oct;26(10):3025-31.Texto completo  Resumo

207. Committee on Gynecologic Practice. ACOG committee opinion no. 727: cascade testing: testing women for known hereditary genetic mutations associated with cancer. Obstet Gynecol. 2018 Jan;131(1):e31-4.Texto completo  Resumo

208. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 Dec;31(12):1623-49.Texto completo  Resumo

209. Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2016 Jul 10;34(20):2416-27.Texto completo  Resumo

210. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. Apr 2025 [internet publication].Texto completo

211. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 Aug 1;28(8):1700-12.Texto completo  Resumo

212. Korde LA, Somerfield MR, Hershman DL, et al. Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 May 20;40(15):1696-8.Texto completo  Resumo

213. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020 Feb 27;382(9):810-21.Texto completo  Resumo

214. Tung NM, Zakalik D, Somerfield MR, et al. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. J Clin Oncol. 2021 Sep 10;39(26):2959-61.Texto completo  Resumo

215. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021 Jun 24;384(25):2394-405.Texto completo  Resumo

216. Emens LA, Adams S, Cimino-Mathews A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 Aug;9(8):e002597.Texto completo  Resumo

217. Freedman RA, Caswell-Jin JL, Hassett M, et al. Optimal adjuvant chemotherapy and targeted therapy for early breast cancer-cyclin-dependent kinase 4 and 6 inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2024 Jun 20;42(18):2233-5.Texto completo  Resumo

218. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233-41.Texto completo  Resumo

219. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014 May 10;32(14):1507-15.Texto completo  Resumo

220. Havel L, Naik H, Ramirez L, et al. Impact of the SSO-ASTRO margin guideline on rates of re-excision after lumpectomy for breast cancer: a meta-analysis. Ann Surg Oncol. 2019 May;26(5):1238-44. Resumo

221. Bundred JR, Michael S, Stuart B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. BMJ. 2022 Sep 21;378:e070346.Texto completo  Resumo

222. The American Society of Breast Surgeons. Resource guide on breast cancer: breast conservation surgery margins​. 2024 [internet publication].Texto completo

223. Kuerer HM, Gwyn K, Ames FC, et al. Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery. 2002 Jan;131(1):108-10. Resumo

224. Framarino-Dei-Malatesta M, Sammartino P, Napoli A. Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus? BMC Cancer. 2017 Nov 21;17(1):777.Texto completo  Resumo

225. Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol. 2004 Jan;15(1):146-50.Texto completo  Resumo

226. Murthy RK, Theriault RL, Barnett CM, et al. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014 Dec 30;16(6):500.Texto completo  Resumo

227. Loibl S, Azim HA Jr, Bachelot T, et al. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC). Ann Oncol. 2023 Oct;34(10):849-66.Texto completo  Resumo

228. Nanda A, Hu J, Hodgkinson S, et al. Oncoplastic breast-conserving surgery for women with primary breast cancer. Cochrane Database Syst Rev. 2021 Oct 29;10(10):CD013658.Texto completo  Resumo

229. Rutherford CL, Barker S, Romics L. A systematic review of oncoplastic volume replacement breast surgery: oncological safety and cosmetic outcome. Ann R Coll Surg Engl. 2022 Jan;104(1):5-17.Texto completo  Resumo

230. Gieni M, Avram R, Dickson L, et al. Local breast cancer recurrence after mastectomy and immediate breast reconstruction for invasive cancer: a meta-analysis. Breast. 2012 Jun;21(3):230-6. Resumo

231. Newman LA, Kuerer HM, Hunt KK, et al. Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol. 1998 Oct-Nov;5(7):620-6. Resumo

232. Medina-Franco H, Vasconez LO, Fix RJ, et al. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg. 2002 Jun;235(6):814-9.Texto completo  Resumo

233. Agha RA, Al Omran Y, Wellstead G, et al. Systematic review of therapeutic nipple-sparing versus skin-sparing mastectomy. BJS Open. 2019 Apr;3(2):135-45.Texto completo  Resumo

234. Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. J Clin Oncol. 2020 Jun 20;38(18):2080-106.Texto completo  Resumo

235. Sadok N, Krabbe-Timmerman IS, de Bock GH, et al. The effect of smoking and body mass index on the complication rate of alloplastic breast reconstruction. Scand J Surg. 2020 Jun;109(2):143-50. Resumo

236. O'Neill AC, Sebastiampillai S, Zhong T, et al. Increasing body mass index increases complications but not failure rates in microvascular breast reconstruction: a retrospective cohort study. J Plast Reconstr Aesthet Surg. 2019 Sep;72(9):1518-24. Resumo

237. Duggal CS, Grudziak J, Metcalfe DB, et al. The effects of breast size in unilateral postmastectomy breast reconstruction. Ann Plast Surg. 2013 May;70(5):506-12. Resumo

238. Hart A, Funderburk CD, Chu CK, et al. The impact of diabetes mellitus on wound healing in breast reconstruction. Ann Plast Surg. 2017 Mar;78(3):260-3. Resumo

239. Wang K, Dai Y, Pan Y, et al. Local-regional recurrence risk after autologous fat grafting in breast cancer patients: a systematic review and meta-analysis. J Surg Oncol. 2020 Mar;121(3):435-40. Resumo

240. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003 Aug 7;349(6):546-53.Texto completo  Resumo

241. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010 Apr;251(4):595-600. Resumo

242. Glechner A, Wöckel A, Gartlehner G, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013 Mar;49(4):812-25. Resumo

243. Solá M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013 Jan;20(1):120-7. Resumo

244. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010 Oct;11(10):927-33.Texto completo  Resumo

245. Julian TB, Anderson SJ, Krag DN, et al. 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. Paper presented at: 2013 ASCO Annual Meeting I. J Clin Oncol. 2013 May 20:31(15 suppl):1000.Texto completo

246. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006 May 3;98(9):599-609.Texto completo  Resumo

247. Bromham N, Schmidt-Hansen M, Astin M, et al. Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev. 2017 Jan 4;1(1):CD004561.Texto completo  Resumo

248. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002 May 15;94(10):2542-51.Texto completo  Resumo

249. Park KU, Somerfield MR, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025 May 10;43(14):1720-41.Texto completo  Resumo

250. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group z0011 randomized trial. Ann Surg. 2010 Sep;252(3):426-32. Resumo

251. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011 Feb 9;305(6):569-75. Resumo

252. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017 Sep 12;318(10):918-26.Texto completo  Resumo

253. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014 Nov;15(12):1303-10. Resumo

254. Sávolt Á, Péley G, Polgár C, et al. Eight-year follow up result of the OTOASOR trial: the Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017 Apr;43(4):672-9. Resumo

255. Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2023 Apr 20;41(12):2159-65.Texto completo  Resumo

256. Choosing Wisely; Society of Surgical Oncology. Five things physicians and patients should question. Jul 2021 [internet publication].Texto completo

257. Gentilini OD, Botteri E, Sangalli C, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023 Nov 1;9(11):1557-64.Texto completo  Resumo

258. Reimer T, Stachs A, Veselinovic K, et al. Axillary surgery in breast cancer - primary results of the INSEMA trial. N Engl J Med. 2025 Mar 13;392(11):1051-64. Resumo

259. Reimer T, Stachs A, Veselinovic K, et al. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): a randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2023 Jan;55:101756.Texto completo  Resumo

260. Filippakis GM, Zografos G. Contraindications of sentinel lymph node biopsy: are there any really? World J Surg Oncol. 2007 Jan 29;5:10.Texto completo  Resumo

261. Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol. 2014 Aug;21(8):2506-11. Resumo

262. Giammarile F, Alazraki N, Aarsvold JN, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1932-47. Resumo

263. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022 Feb 10;386(6):556-67.Texto completo  Resumo

264. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519-30. Resumo

265. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. Resumo

266. Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008 May-Jun;14(3):250-4. Resumo

267. Gentilini O, Cremonesi M, Trifirò G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004 Sep;15(9):1348-51.Texto completo  Resumo

268. Keleher A, Wendt R 3rd, Delpassand E, et al. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004 Nov-Dec;10(6):492-5. Resumo

269. Zalewska K, Skonieczna M, Nejc D, et al. Is the superparamagnetic approach equal to radioisotopes in sentinel lymph node biopsy? The over-collecting node issue in breast cancer patients. J Clin Med. 2025 May 1;14(9):3148.Texto completo  Resumo

270. Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015 Aug 1;121(15):2544-52.Texto completo  Resumo

271. Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015 Jun;220(6):1063-9. Resumo

272. Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021 May 1;39(13):1485-505.Texto completo  Resumo

273. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27-39.Texto completo  Resumo

274. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002.Texto completo  Resumo

275. van Nes JG, Putter H, Julien JP, et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009 May;115(1):101-13. Resumo

276. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001 Dec 1;(30):96-102.Texto completo  Resumo

277. Esserman LJ, Berry DA, Demichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10;30(26):3242-9.Texto completo  Resumo

278. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. Resumo

279. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275-81.Texto completo  Resumo

280. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 May 20;30(15):1796-804.Texto completo  Resumo

281. Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020 Mar;84:101965.Texto completo  Resumo

282. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005 Jun 1;23(16):3686-96.Texto completo  Resumo

283. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83. Resumo

284. Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009 May 20;27(15):2474-81. Resumo

285. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008 Jan 1;26(1):44-53.Texto completo  Resumo

286. Francis P, Crown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008 Jan 16;100(2):121-33.Texto completo  Resumo

287. Martín M, Rodríguez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14.Texto completo  Resumo

288. Shao N, Wang S, Yao C, et al. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. Breast. 2012 Jun;21(3):389-93. Resumo

289. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71.Texto completo  Resumo

290. Qin YY, Li H, Guo XJ, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One. 2011 Nov 1;6(11):e26946.Texto completo  Resumo

291. Peto R, Davies C, Godwin J, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012 Feb 4;379(9814):432-44. Resumo

292. Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017 Aug 10;35(23):2647-55.Texto completo  Resumo

293. Willson ML, Burke L, Ferguson T, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2019 Sep 2;(9):CD004421.Texto completo  Resumo

294. Eiermann W, Pienkowski T, Crown J, et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84.Texto completo  Resumo

295. Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3;362(22):2053-65.Texto completo  Resumo

296. Zaheed M, Wilcken N, Willson ML, et al. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2019 Feb 18;(2):CD012873.Texto completo  Resumo

297. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Resumo

298. Goldhirsch A, Colleoni M, Coates AS, et al; International Breast Cancer Study Group (IBCSG). Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? Ann Oncol. 1998 May;9(5):489-93.Texto completo  Resumo

299. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1;24(34):5381-7.Texto completo  Resumo

300. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide Is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar 10;27(8):1177-83. Resumo

301. Ding W, Li Z, Wang C, et al. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2018 Oct;97(42):e12908.Texto completo  Resumo

302. Isaac N, Panzarella T, Lau A, et al. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen. Cancer. 2002 Aug 15;95(4):696-703.Texto completo  Resumo

303. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010 Jan 30;375(9712):377-84. Resumo

304. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. Resumo

305. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84.Texto completo  Resumo

306. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791-800. Resumo

307. Swain SM, Ewer MS, Viale G, et al; BERENICE Study Group. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018 Mar 1;29(3):646-53.Texto completo  Resumo

308. Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018 Jan;89:27-35. Resumo

309. Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):115-26. Resumo

310. Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol. 2019 Sep 1;37(25):2206-16.Texto completo  Resumo

311. Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol. 2020 Mar 1;6(3):e193692.Texto completo  Resumo

312. Chen S, Liang Y, Feng Z, et al. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis. BMC Cancer. 2019 Oct 21;19(1):973.Texto completo  Resumo

313. van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 Dec;19(12):1630-40. Resumo

314. van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021 Jul 1;7(7):978-84.Texto completo  Resumo

315. Jackisch C, Hegg R, Stroyakovskiy D, et al. HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. Eur J Cancer. 2016 Jul;62:62-75.Texto completo  Resumo

316. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 Mar 25;389(10075):1195-205.Texto completo  Resumo

317. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet. 2019 Jun 29;393(10191):2591-8. Resumo

318. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019 Feb 14;380(7):617-28.Texto completo  Resumo

319. Morgan J, Wyld L, Collins KA. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2014 May 16;(5):CD004272.Texto completo

320. Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016 Nov 1;2(11):1477-86.Texto completo  Resumo

321. Hunt KK, Suman VJ, Wingate HF, et al. Local-regional recurrence after neoadjuvant endocrine therapy: data from ACOSOG Z1031 (alliance), a randomized phase 2 neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-positive clinical stage 2 or 3 breast cancer. Ann Surg Oncol. 2023 Apr;30(4):2111-8.Texto completo  Resumo

322. National Comprehensive Cancer Network. NCCN guideline management of immunotherapy-related toxicities. [internet publication].Texto completo

323. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021 Jun;9(6):e002435.Texto completo  Resumo

324. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021 Dec 20;39(36):4073-126.Texto completo  Resumo

325. Mason SR, Willson ML, Egger SJ, et al. Platinum-based chemotherapy for early triple-negative breast cancer. Cochrane Database Syst Rev. 2023 Sep 8;9(9):CD014805.Texto completo  Resumo

326. Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol. 2001 Jun 15;19(12):3103-10. Resumo

327. Martin M, Pienkowski T, Mackey J, et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13.Texto completo  Resumo

328. Nitz U, Gluz O, Clemens M, et al. West German Study PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol. 2019 Apr 1;37(10):799-808. Resumo

329. Henry NL, Somerfield MR, Abramson VG, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: update of the ASCO endorsement of the Cancer Care Ontario guideline. J Clin Oncol. 2019 Aug 1;37(22):1965-77.Texto completo  Resumo

330. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016 Aug 25;375(8):717-29.Texto completo  Resumo

331. Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat. 2017 Oct;165(3):573-83.Texto completo  Resumo

332. Esserman LJ, Yau C, Thompson CK, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol. 2017 Nov 1;3(11):1503-10.Texto completo  Resumo

333. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-59.Texto completo  Resumo

334. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019 Apr 6;393(10179):1440-52.Texto completo  Resumo

335. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83.Texto completo  Resumo

336. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52.Texto completo  Resumo

337. Shen Y, Fujii T, Ueno NT, et al. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat. 2019 Jan;173(1):1-9.Texto completo  Resumo

338. Wilson FR, Coombes ME, Brezden-Masley C, et al. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Syst Rev. 2018 Nov 14;7(1):191.Texto completo  Resumo

339. Tolaney SM, Tarantino P, Graham N, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 Mar;24(3):273-85. Resumo

340. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-31.Texto completo  Resumo

341. Loibl S, Jassem J, Sonnenblick A, et al. Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update. J Clin Oncol. 2024 Nov;42(31):3643-51.Texto completo  Resumo

342. Tolaney S, Barry WT, Dang CT, et al. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Res. 2013;73(suppl 24):abstract S1-04.Texto completo

343. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 8;372(2):134-41.Texto completo  Resumo

344. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al; Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21;382(9897):1021-8. Resumo

345. Pivot X, Romieu G, Debled M, et al; PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013 Jul;14(8):741-8. Resumo

346. Goldvaser H, Korzets Y, Shepshelovich D, et al. Deescalating adjuvant trastuzumab in HER2-positive early-stage breast cancer: a systemic review and meta-analysis. JNCI Cancer Spectr. 2019 May 11;3(2):pkz033.Texto completo  Resumo

347. Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018 Sep 1;4(9):1199-206.Texto completo  Resumo

348. Chen L, Zhou W, Hu X, et al. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2019 May;75:12-9.Texto completo  Resumo

349. Inno A, Barni S, Ghidini A, et al. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019 Jan;173(2):247-54. Resumo

350. Migliavacca Zucchetti B, Nicolò E, Curigliano G. Biosimilars for breast cancer. Expert Opin Biol Ther. 2019 Oct;19(10):1015-21. Resumo

351. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):367-77. Resumo

352. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-700. Resumo

353. Denduluri N, Somerfield MR, Chavez-MacGregor M, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update. J Clin Oncol. 2021 Feb 20;39(6):685-93.Texto completo  Resumo

354. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19;374(9707):2055-63. Resumo

355. Alkner S, Bendahl PO, Ferno M, et al. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur J Cancer. 2009 Sep;45(14):2496-502. Resumo

356. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022 Mar;23(3):382-92.Texto completo  Resumo

357. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018 Jul 12;379(2):122-37.Texto completo  Resumo

358. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18.Texto completo  Resumo

359. Kim HA, Lee JW, Nam SJ, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial. J Clin Oncol. 2020 Feb 10;38(5):434-43.Texto completo  Resumo

360. Pagani O, Walley BA, Fleming GF, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol. 2023 Mar 1;41(7):1376-82.Texto completo  Resumo

361. Bui KT, Willson ML, Goel S, et al. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev. 2020 Mar 6;(3):CD013538.Texto completo  Resumo

362. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805-16.Texto completo  Resumo

363. Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013 Jun 20;31(18) suppl: abstr 5.Texto completo

364. Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017 Nov 9;377(19):1836-46.Texto completo  Resumo

365. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92.Texto completo  Resumo

366. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2. Resumo

367. Forbes JF, Cuzick J, Buzdar A, et al; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008 Jan;9(1):45-53. Resumo

368. Joerger M, Thurlimann B. Update of the BIG 1-98 Trial: where do we stand? Breast. 22009 Oct;18 Suppl 3:S78-82. Resumo

369. Ruhstaller T, Giobbie-Hurder A, Colleoni M, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019 Jan 10;37(2):105-14.Texto completo  Resumo

370. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016 Jul 21;375(3):209-19.Texto completo  Resumo

371. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019 Feb 10;37(5):423-38.Texto completo  Resumo

372. Mamounas EP, Bandos H, Lembersky BC, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):88-99.Texto completo  Resumo

373. Del Mastro L, Mansutti M, Bisagni G, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Oct;22(10):1458-67. Resumo

374. Gnant M, Fitzal F, Rinnerthaler G, et al. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med. 2021 Jul 29;385(5):395-405.Texto completo  Resumo

375. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020 Dec 1;38(34):3987-98.Texto completo  Resumo

376. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024 Mar 21;390(12):1080-91.Texto completo  Resumo

377. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024 Mar 20;42(9):987-93.Texto completo  Resumo

378. Darby S, McGale P, Correa C, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707-16.Texto completo  Resumo

379. Sedlmayer F, Sautter-Bihl ML, Budach W, et al. DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol. 2013 Oct;189(10):825-33.Texto completo  Resumo

380. Korzets Y, Fyles A, Shepshelovich D, et al. Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019 Jun;175(3):531-45. Resumo

381. Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019 Dec 14;394(10215):2155-64.Texto completo  Resumo

382. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015 Jul 23;373(4):307-16. Resumo

383. Whelan TJ, Olivotto IA, Levine MN. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015 Nov 5;373(19):1878-9. Resumo

384. Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: A population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016 Feb 1;34(4):314-20.Texto completo  Resumo

385. Kindts I, Laenen A, Depuydt T, et al. Tumour bed boost radiotherapy for women after breast-conserving surgery. Cochrane Database Syst Rev. 2017 Nov 6;(11):CD011987.Texto completo  Resumo

386. Haussmann J, Budach W, Corradini S, et al. Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials. Radiat Oncol. 2023 Nov 2;18(1):181.Texto completo  Resumo

387. Shaitelman SF, Anderson BM, Arthur DW, et al. Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2024 Mar-Apr;14(2):112-32.Texto completo  Resumo

388. Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 1;27(16):2638-44. Resumo

389. Bentzen SM, Agrawal RK, Aird EG, et al; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008 Apr;9(4):331-41.Texto completo  Resumo

390. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013 Oct;14(11):1086-94.Texto completo  Resumo

391. Bentzen SM, Agrawal RK, Aird EG, et al; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008 Mar 29;371(9618):1098-107.Texto completo  Resumo

392. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010 Feb 11;362(6):513-20.Texto completo  Resumo

393. Hickey BE, James ML, Lehman M, et al. Hypofractionated radiation therapy for early breast cancer. Cochrane Database Syst Rev. 2016 Jul 18;(7):CD003860.Texto completo  Resumo

394. Andrade TRM, Fonseca MCM, Segreto HRC, et al. Meta-analysis of long-term efficacy and safety of hypofractionated radiotherapy in the treatment of early breast cancer. Breast. 2019 Dec;48:24-31. Resumo

395. Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020 May 23;395(10237):1613-26.Texto completo  Resumo

396. Brunt AM, Haviland JS, Sydenham M, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol. 2020 Oct 1;38(28):3261-72.Texto completo  Resumo

397. Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence Trial. J Clin Oncol. 2020 Dec 10;38(35):4175-83.Texto completo  Resumo

398. Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019 Dec 14;394(10215):2165-72. Resumo

399. Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017 Sep 9;390(10099):1048-60.Texto completo  Resumo

400. Strnad V, Polgár C, Ott OJ, et al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023 Mar;24(3):262-72. Resumo

401. Offersen BV, Alsner J, Nielsen HM, et al. Partial breast irradiation versus whole breast irradiation for early breast cancer patients in a randomized phase III trial: the Danish Breast Cancer Group partial breast irradiation trial. J Clin Oncol. 2022 Dec 20;40(36):4189-97.Texto completo  Resumo

402. Polgár C, Major T, Takácsi-Nagy Z, et al. Breast-conserving surgery followed by partial or whole breast irradiation: twenty-year results of a phase 3 clinical study. Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):998-1006. Resumo

403. Shumway DA, Corbin KS, Farah MH, et al. Partial breast irradiation compared with whole breast irradiation: a systematic review and meta-analysis. J Natl Cancer Inst. 2023 Sep 7;115(9):1011-9.Texto completo  Resumo

404. Franceschini D, Loi M, Chiola I, et al. Preliminary results of a randomized study on postmenopausal women with early stage breast cancer: adjuvant hypofractionated whole breast irradiation versus accelerated partial breast irradiation (HYPAB Trial). Clin Breast Cancer. 2021 Jun;21(3):231-8. Resumo

405. Polgár C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):259-68. Resumo

406. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005 Jan 19;97(2):116-26.Texto completo  Resumo

407. McGale P, Taylor C, Correa C, et al; EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Jun 21;383(9935):2127-35.Texto completo  Resumo

408. Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):352-60. Resumo

409. Overgaard M, Nielsen HM, Tramm T, et al. Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial. Radiother Oncol. 2022 May;170:4-13.Texto completo  Resumo

410. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023 Nov 25;402(10416):1991-2003.Texto completo  Resumo

411. Jimenez RB, Abdou Y, Anderson P, et al. Postmastectomy radiation therapy: an ASTRO/ASCO/SSO clinical practice guideline. Ann Surg Oncol. 2025 Sep 16.Texto completo  Resumo

412. Verma R, Chandarana M, Barrett J, et al. Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes. Cochrane Database Syst Rev. 2023 Jun 16;6(6):CD014463.Texto completo  Resumo

413. Wang K, Jin X, Wang W, et al. The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis. BMC Cancer. 2021 Jun 25;21(1):728.Texto completo  Resumo

414. Kanis JA, McCloskey EV, Powles T, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999 Mar;79(7-8):1179-81. Resumo

415. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006 Aug;21(8):1215-23.Texto completo  Resumo

416. Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019 Nov 1;37(31):2916-46.Texto completo  Resumo

417. Eisen A, Somerfield MR, Accordino MK, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol. 2022 Mar 1;40(7):787-800.Texto completo  Resumo

418. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012 Mar 1;118(5):1192-201. Resumo

419. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011 Oct 13;365(15):1396-405. Resumo

420. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013 Feb;24(2):398-405. Resumo

421. O'Carrigan B, Wong MH, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017 Oct 30;(10):CD003474.Texto completo  Resumo

422. Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):339-51. Resumo

423. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015 Oct 3;386(10001):1353-61.Texto completo  Resumo

424. Gralow JR, Barlow WE, Paterson AHG, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst. 2020 Jul 1;112(7):698-707.Texto completo  Resumo

425. Friedl TWP, Fehm T, Müller V, et al. Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial. JAMA Oncol. 2021 Aug 1;7(8):1149-57.Texto completo  Resumo

426. U.S. Food and Drug Administration. FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab). Feb 2024 [internet publication].Texto completo

427. American College of Radiology. ACR appropriateness criteria: stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. 2019 [internet publication].Texto completo

428. American College of Radiology. ACR appropriateness criteria: local-regional recurrence (LRR) and salvage surgery - breast cancer. 2013 [internet publication].Texto completo

429. Aebi S, Gelber S, Anderson SJ, et al; CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014 Feb;15(2):156-63.Texto completo  Resumo

430. Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol. 2020 Jun 1;38(16):1849-63.Texto completo  Resumo

431. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6.Texto completo  Resumo

432. Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018 Feb 1;29(2):405-17.Texto completo  Resumo

433. Borgen PI, Wong GY, Vlamis V, et al. Current management of male breast cancer. A review of 104 cases. Ann Surg. 1992 May;215(5):451-7.Texto completo  Resumo

434. Cloyd JM, Hernandez-Boussard T, Wapnir IL. Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009. Ann Surg Oncol. 2013 May;20(5):1545-50. Resumo

435. Sauder CAM, Bateni SB, Davidson AJ, et al. Breast conserving surgery compared with mastectomy in male breast cancer: a brief systematic review. Clin Breast Cancer. 2020 Jun;20(3):e309-14. Resumo

436. Den J, Nelson N, Khanipov K, et al. Breast conservation surgery for breast cancer in men. J Am Coll Surg. 2025 Apr 1;240(4):627-35. Resumo

437. Rusby JE, Smith BL, Dominguez FJ, et al. Sentinel lymph node biopsy in men with breast cancer: a report of 31 consecutive procedures and review of the literature. Clin Breast Cancer. 2006 Dec;7(5):406-10. Resumo

438. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005 Dec 1;104(11):2359-64.Texto completo  Resumo

439. Cimmino VM, Degnim AC, Sabel MS, et al. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol. 2004 May 1;86(2):74-7. Resumo

440. Boughey JC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006 Oct;203(4):475-80. Resumo

441. Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013 Jan;137(2):465-70. Resumo

442. Den J, Nelson N, Khanipov K, et al. Breast conservation surgery for breast cancer in Men. J Am Coll Surg. 2025 Apr 1;240(4):627-35. Resumo

443. Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol. 2023 Apr 20;41(12):2159-65.Texto completo  Resumo

444. Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2019 Aug 1;37(22):1868-75.Texto completo  Resumo

445. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities [internet publication]​.Texto completo

446. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92.Texto completo  Resumo

447. Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022 Mar;33(3):321-9.Texto completo  Resumo

448. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Resumo

449. Untch M, von Minckwitz G, Gerber B, et al. Survival analysis after neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer in the GeparQuinto (G5) study (GBG 44). J Clin Oncol. 2018 May 1;36(13):1308-16. Resumo

450. ClinicalTrials.gov. Evaluation of IPI-549 combined with front-line treatments in patients with triple-negative breast cancer or renal cell carcinoma (MARIO-3). Aug 2023 [internet publication].Texto completo

451. Orecchia R, Veronesi U, Maisonneuve P, et al. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. Lancet Oncol. 2021 May;22(5):597-608. Resumo

452. Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014 Feb 15;383(9917):603-13.Texto completo  Resumo

453. National Institute for Health and Care Excellence. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer. Jan 2018 [internet publication].Texto completo

454. Wang F, Shu X, Meszoely I, et al. Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncol. 2019 Sep 19;5(11):1589-96.Texto completo  Resumo

455. Huang W, Ran R, Shao B, et al. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019 Nov;178(1):17-33. Resumo

456. Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018 Jun 1;110(6):560-7.Texto completo  Resumo

457. Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019 Mar 1;37(7):559-69.Texto completo  Resumo

458. Kovács A, Stenmark Tullberg A, Werner Rönnerman E, et al. Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes: a long-term follow-up of the SweBCG91RT randomized trial. J Clin Oncol. 2019 May 10;37(14):1179-87.Texto completo  Resumo

459. Li S, He Y, Li C, et al. The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: a meta-analysis. Medicine (Baltimore). 2020 Mar;99(10):e19345.Texto completo  Resumo

460. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994 Jan 15;120(2):104-10. Resumo

461. Louwman WJ, Janssen-Heijnen ML, Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer. 2005 Mar;41(5):779-85. Resumo

462. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997 Jan;15(1):103-9. Resumo

463. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017 Oct 1;35(28):3240-61.Texto completo  Resumo

464. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015 Oct 1;33(28):3199-212.Texto completo  Resumo

465. Carroll J, Protani M, Walpole E, et al. Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review. Breast Cancer Res Treat. 2012 Nov;136(2):323-30. Resumo

466. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections [internet publication].Texto completo

467. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May;14(5):1718-29. Resumo

468. Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018 Jul 1;36(19):1981-90.Texto completo  Resumo

469. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016 Jan;2(1):65-73.Texto completo  Resumo

470. Su HI, Lacchetti C, Letourneau J, et al. Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol. 2025 Apr 20;43(12):1488-515.Texto completo  Resumo

471. Von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977 Feb;62(2):200-8. Resumo

472. Ryberg M, Nielsen DL, Cortese G, et al. Epirubicin (E) cardiac toxicity: a retrospective analysis of 1,097 patients (pts) treated for metastatic breast cancer (MBC). Paper presented at: 2007 ASCO Annual Meeting. J Clin Oncol. 2007;25(18S-June 20 suppl):1029.Texto completo

473. Guglin M, Hartlage G, Reynolds C, et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009 Oct;15(8):651-7. Resumo

474. Yu AF, Flynn JR, Moskowitz CS, et al. Long-term cardiopulmonary consequences of treatment-induced cardiotoxicity in survivors of ERBB2-positive breast cancer. JAMA Cardiol. 2020 Jan 15;5(3):309-17. Resumo

475. Kaboré EG, Guenancia C, Vaz-Luis I, et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med. 2019 Dec 23;16(12):e1002989.Texto completo  Resumo

476. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96(2):133-9. Resumo

477. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003 Apr 1;21(7):1195-204. Resumo

478. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007 Sep 1;25(25):3871-6. Resumo

479. Okwuosa TM, Morgans A, Rhee JW, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021 Jun;14(3):e000082.Texto completo  Resumo

480. Goldvaser H, Barnes TA, Šeruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018 Jan 1;110(1).Texto completo  Resumo

481. Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018 Oct 8;363:k3845.Texto completo  Resumo

482. Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017 Mar 1;28(3):487-96.Texto completo  Resumo

483. He Y, Zhang J, Shen G, et al. Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019 Oct 29;20(1):62.Texto completo  Resumo

484. Haque R, Shi J, Schottinger JE, et al. Cardiovascular disease after aromatase inhibitor use. JAMA Oncol. 2016 Dec 1;2(12):1590-7.Texto completo  Resumo

485. Khosrow-Khavar F, Filion KB, Bouganim N, et al. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study. Circulation. 2020 Feb 18;141(7):549-59.Texto completo  Resumo

486. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007 Mar 1;25(7):829-36.Texto completo  Resumo

487. Price J, Purtell JR. Prevention and treatment of lymphedema after breast cancer. Am J Nurs. 1997 Sep;97(9):34-7. Resumo

488. McNeely ML, Campbell K, Ospina M, et al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005211.Texto completo  Resumo

489. Markkula SP, Leung N, Allen VB, et al. Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. Cochrane Database Syst Rev. 2019 Feb 19;(2):CD011433.Texto completo  Resumo

490. Co M, Lee A, Kwong A. Cutaneous angiosarcoma secondary to lymphoedema or radiation therapy - a systematic review. Clin Oncol (R Coll Radiol). 2019 Apr;31(4):225-31. Resumo

491. Smile TD, Tendulkar R, Schwarz G, et al. A review of treatment for breast cancer-related lymphedema: paradigms for clinical practice. Am J Clin Oncol. 2018 Feb;41(2):178-90. Resumo

492. Dayes IS, Whelan TJ, Julian JA, et al. Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. J Clin Oncol. 2013 Oct 20;31(30):3758-63.Texto completo  Resumo

493. Schneider BP, Zhao F, Ballinger TJ, et al. ECOG-ACRIN EAZ171: prospective validation trial of germline predictors of taxane-induced peripheral neuropathy in black women with early-stage breast cancer. J Clin Oncol. 2024 Aug 20;42(24):2899-907.Texto completo  Resumo

494. Cianfrocca M, Flatters SJ, Bennett GJ, et al. Peripheral neuropathy in a woman with breast cancer. J Pain. 2006 Jan;7(1):2-10. Resumo

495. van Deventer H, Bernard S. Use of gabapentin to treat taxane-induced myalgias. J Clin Oncol. 1999 Jan;17(1):434-5.Texto completo  Resumo

496. Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother. 2005 Jun;6(7):1095-106. Resumo

497. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000 Dec 16;356(9247):2059-63. Resumo

498. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.Texto completo  Resumo

499. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005 Sep 3-9;366(9488):818-24. Resumo

500. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000 May 16;132(10):788-93. Resumo

501. Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 2008 Apr 1;26(10):1650-6.Texto completo  Resumo

502. Wang K, Yee C, Tam S, et al. Prevalence of pain in patients with breast cancer post-treatment: A systematic review. Breast. 2018 Dec;42:113-27. Resumo

503. Wang L, Guyatt GH, Kennedy SA, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ. 2016 Oct 4;188(14):E352-61.Texto completo  Resumo

504. Khan JS, Ladha KS, Abdallah F, et al. Treating persistent pain after breast cancer surgery. Drugs. 2020 Jan;80(1):23-31. Resumo

505. Moschetti I, Cinquini M, Lambertini M, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2016 May 27;2016(5):CD001768.Texto completo  Resumo

506. Khatcheressian JL, Hurley P, Bantug E, et al; American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 1;31(7):961-5.Texto completo  Resumo

507. Lu WL, Jansen L, Post WJ, et al. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009 Apr;114(3):403-12. Resumo

508. Choosing Wisely; American Society for Radiation Oncology. Follow-up mammograms following radiotherapy for breast conservation. Sep 2021 [internet publication].Texto completo

509. American College of Radiology. ACR appropriateness criteria: imaging after breast surgery. 2022 [internet publication].Texto completo

510. American College of Radiology. ACR appropriateness criteria: imaging after mastectomy and breast reconstruction. 2020 [internet publication].Texto completo

511. Partridge AH, Niman SM, Ruggeri M, et al. Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021 Oct;59:327-38.Texto completo  Resumo

512. Partridge AH, Niman SM, Ruggeri M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023 May 4;388(18):1645-56.Texto completo  Resumo

513. Spronk I, Schellevis FG, Burgers JS, et al. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. Breast. 2018 Jun;39:70-9. Resumo

514. Akdeniz D, Schmidt MK, Seynaeve CM, et al. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast. 2019 Apr;44:1-14. Resumo

515. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-507.Texto completo  Resumo

516. Rock CL, Thomson CA, Sullivan KR, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 2022 May;72(3):230-62.Texto completo  Resumo

517. Soares Falcetta F, de Araújo Vianna Träsel H, de Almeida FK, et al. Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2018 Aug;170(3):455-76. Resumo

518. Chlebowski RT, Aragaki AK, Anderson GL, et al. Dietary modification and breast cancer mortality: long-term follow-up of the Women's Health Initiative randomized trial. J Clin Oncol. 2020 May 1;38(13):1419-28. Resumo

519. Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer - systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014 Oct;25(10):1901-14.Texto completo  Resumo

520. Siegel A, Bremer RC, Klein WMP, et al. Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome. Breast Cancer Res Treat. 2022 Jan;191(1):159-67. Resumo

521. Yadav S, Boddicker NJ, Na J, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 Mar 20;41(9):1703-13.Texto completo  Resumo

522. Morra A, Mavaddat N, Muranen TA, et al. The impact of coding germline variants on contralateral breast cancer risk and survival. Am J Hum Genet. 2023 Mar 2;110(3):475-86.Texto completo  Resumo

523. Smith-Gagen J, Carrillo JE, Ang A, et al. Practices that reduce the Latina survival disparity after breast cancer. J Womens Health (Larchmt). 2013 Nov;22(11):938-46. Resumo

524. Buist DS, Bosco JL, Silliman RA, et al. Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer. Breast Cancer Res Treat. 2013 Nov;142(1):153-63. Resumo